220 results about "Primary liver cancer" patented technology

A system has been constructed that recapitulate the features of a capillary bed through normal human tissue. The system facilitates perfusion of three-dimensional (3D) cell monocultures and heterotypic cell co-cultures at the length scale of the capillary bed. A major feature is that the system can be utilized within a “multiwell plate” format amenable to high-throughput assays compatible with the type of robotics commonly used in pharmaceutical development. The system provides a means to conduct assays for toxicology and metabolism and as a model for human diseases such as hepatic diseases, including hepatitis, exposure-related pathologies, and cancer. Cancer applications include primary liver cancer as well as metastases. The system can also be used as a means of testing gene therapy approaches for treating disease and inborn genetic defects.

The invention discloses a male multi-tumor marker detection protein chip and a kit thereof. The chip comprises a substrate, protein markers distributed in an array type and point coatings of contrasts, wherein the substrate is a glass substrate or a film substrate; and the tumor markers and the point coatings of the contrasts are seven protein markers of AFP, CEA, NSE, CYFRA21-1, CA19-9, tPSA and SCC-ag, a positive contrast and a negative contrast which are uniformly distributed and latticed on the substrate. A reaction result of various indexes can be obtained only through one reaction by utilizing the protein chip, and the following tumors can be simultaneously screened: primary liver cancer, prostatic cancer, pancreatic cancer, lung cancer, esophageal cancer, gastric cancer and colorectal cancer. The invention is particularly suitable for the general examination of malignant tumors of male asymptomatic groups and high risk groups.

A methylation state information about CpG island in the promoter region of the gene associated with primary liver cancer, its use and the method and reagent kit for detecting primary liver cancer aredisclosed. Said reagent kit contains the methylation-specific restriction endonuclease and the promoter CpG island-specific primer pair of the gene associated with liver cancer, or the reagent for transforming the methylation cytosine to uracil and the primer for the promoter CpG island of the gene associated with liver cancer. Said genes are also disclosed.

The invention relates to 9 microRNA markers for predicting whether the primary liver cancer relapses, in particular to a kind of microRNA markers for predicting whether the primary liver cancer relapses. The tests prove that the specific microRNA markers can very effectively distinguish the samples with relapse and the samples without relapse of the primary liver cancer. The invention also relates to a chip and a kit for detecting the microRNA markers.

The Chinese medicine for treating hepatocirrhosis, hepatitis and liver cancer is prepared with main material, subsidiary material and supplementary material and may be granule or mixture. The main material is polystictus versicolar extractive and the supplementary material is compound Qiupi cream. The medicine has the functions of strengthening body's resistance and eliminating evil, regulating body's inside environment comprehensively. It has excellent curative effect on chronic active hepatitis, sustained AFP positive, and primary liver cancer in stage I and II.

The invention relates to the field of diagnosis and treatment of liver cirrhosis and liver fibrosis, in particular to application of Golgi protein 73(GP73) and matter for detecting the concentration of the Golgi protein 73(GP73) in preparation of products for screening or auxiliarily diagnosing liver cirrhosis or liver fibrosis related diseases or products for auxiliarily judging prognosis of the diseases. It is proved that the Golgi protein 73(GP73) can serve as a novel liver cirrhosis marker, also has diagnosis value on liver cirrhosis caused by non-b hepatitis virus infection, and has no diagnosis value on primary liver cancer.

The invention discloses a kit for detecting an anti-GP73 antibody in serum, and belongs to the technical fields of medicines and biology. The kit comprises GP73 protein antigen, confining liquid, GP73 protein antigen of an enzyme label, a rabbit anti-human GP73 polyclonal antibody standard, a coating buffer, a developing solution, a scrubbing solution, a stop solution and a diluent, wherein the GP73 protein antigen has an amino acid sequence as shown in a sequence table SEQIDNO:1. According to the kit, the concentration of the anti-GP73 antibody in the serum of a patient can be accurately calculated, the existential level of the anti-GP73 antibody in the serum is really reflected, the kit can be applied to diagnosis of primary liver cancer in clinic, and the process of molecular change of the tumor can also be reflected by detecting the level of the anti-GP73 antibody, thereby judging the autoimmune response capacity of a silk body. The kit disclosed by the invention also has the advantages of good specificity, and high sensitivity, accuracy and precision.

The invention discloses a stem cell preparation for treating primary liver cancer and a preparation method thereof. The preparation contains (60-100)*10<6> pieces/ml of mesenchymal stem cells, 20ng/ml of HGF and 10ng/ml of FGF-4, and takes autologous platelet-rich plasma lysate as a solvent. The preparation method comprises the following steps of: (1) collecting an umbilical cord, and carrying out primary culture to obtain cells; (2) detecting by using a flow cytometry, wherein such cells express CD29, CD73, CD90 and CD105; (3) collecting cells, namely dissolving (60-100)*10<6> mesenchymal stem cells of the human umbilical cord in 1 ml of autologous platelet-rich plasma lysate, and adding 20ng of HGF and 10ng of FGF-4 to be prepared into 1 ml of a stem cell preparation. According to the stem cell preparation disclosed by the invention, the source of raw materials is rich, the raw materials are easy to obtain, the umbilical cord mesenchymal stem cells are weakly immunogenic, and platelet-rich plasma is taken from the patients, so no immunogenicity exists.

The invention discloses an lncRNA gene marker and a kit for early diagnosis on primary liver cancer. The lncRNA gene marker consists of an lncRNA MEG3 and lncRNA PRNCR1. When being used for cooperatively diagnosing primary liver cancer and non-primary liver cancer (including benign liver diseases and health control), the plasma lncRNA MEG3 and lncRNA PRNCR1 of the gene marker are excellent in diagnosis performance, high in accuracy and sensitivity and good in specificity, and can be developed into a diagnosis kit for early diagnosis on the primary liver cancer.

A freeze-dried hydroxy camptothecin powder injection for treating primary liver cancer, gastrointestinal cancer, vesical cancer, lung cancer, leukemia, etc is prepared from hydroxy camptothecin, aminoacetic acid, lactose, sodium hydroxide and the water for injection through preparing buffer liquid from sodium hydroxide, aminoacetic acid and the water for injection, dissolving hydroxy camptothecinin it to obtain solution A, dissolving lactose in the water for injection to obtain solution B, adding A and rest of aminoacetic acid to B, stirring, regulating pH value, adding water for injection, filtering loading in containers, freeze drying and sealing.

The invention relates to a pharmaceutical composition for treating cancers, a pharmaceutical preparation as well as applications and production methods thereof. The pharmaceutical composition and the pharmaceutical preparation respectively contain a ginseng monomer component, an Astragalus root monomer component, a manyprickle acanthopanax monomer component and a blister beetle monomer component as well as optionally blister beetle monomer derivatives which are added as required. Preferably, the pharmaceutical composition and the pharmaceutical preparation contain 200 to 300 parts by weight of ginseng saponin monomer, 48 to 72 parts by weight of Astragalus root monomer, 60 to 90 parts by weight of manyprickle acanthopanax monomer and 4.2 to 6.3 parts by weight of blister beetle monomer. The pharmaceutical preparation is prepared by the conventional preparation process from the Chinese medicine extracts mentioned above and optionally blister beetle monomer derivatives in addition with adjuvant materials. The pharmaceutical composition and the pharmaceutical preparation thereof, provided by the invention, are used for treating various cancers, such as primary liver cancer, lung cancer, rectal cancer, malignant lymphoma and gynecological malignant tumors, show unexpected curative effects, and can achieve both cancer therapy and immunity enhancement and at the same time reduce the toxicity.

The compound dioecious balanophora herb capsule is prepared with dioecious balanophora herb, airpotato yam, Chinese trichosannthes root, smiacis glabrae, flavescent sophora root and stink bug in certain weight proportion. The present invention has taking convenience and small dosage. The present invention possesses functions of soothing the liver, dispersing the depressed vital energy, promoting blood circulation and detoxicating, and is used in treating primary liver cancer caused by depressed liver, Qi stagnation and poison stasis.

The invention discloses a polyvinyl alcohol nanofiber emboliaztion agent as well as a preparation method and application thereof and belongs to the field of vascular thrombosis materials for interventional therapy. The polyvinyl alcohol nanofiber emboliaztion agent consists of polyvinyl alcohol electrostatic spinning nanofiber granules, wherein the particle sizes of the nanofiber granules is 100-300mu m. The preparation method comprises the following steps: dissolving polyvinyl alcohol granules into water, and heating till the polyvinyl alcohol granules are completely dissolved so as to obtaina polyvinyl alcohol solution of an appropriate concentration as an electrostatic spinning solution; preparing a polyvinyl alcohol nanofiber film from the electrostatic spinning solution by using electrostatic spinning equipment; performing thermal treatment on the nanofiber film; shearing the nanofiber film after thermal treatment, performing low-temperature crushing treatment, and screening, thereby obtaining the polyvinyl alcohol nanofiber granules of which the particle size is 100-300mu m. The emboliaztion agent disclosed by the invention has relatively good treatment effects and biological security, and can be also applied to arterial embolism of various types of malignant tumor such as primary liver cancer and kidney cancer.

The invention discloses a human hepatocellular carcinoma cell line, and an establishing method and application thereof. The human hepatocellular carcinoma cell line is preserved in China Center for Type Culture Collection with an accession number of CCTCC No: C201114. The establishing method comprises the following steps: 1) acquiring a fresh clinical liver cancer excision specimen, cutting the specimen into small blocks with sizes in a range of 20 to 50 mg and inoculating mammals with the small blocks; and 2) in 70 to 90 d after inoculation, killing tumor-bearing mammals, taking out tumor tissue and carrying out primary culture and subculturing of cancer cells. The human hepatocellular carcinoma cell line provided by the invention has stable properties and tumorigenicity, can realize stable several passages and successful preparation of a liver cancer animal model, can be used for analyzing in-vivo and in-vitro drug susceptibility so as to further realize establishment of mutually-related in-vivo and in-vitro drug screening platforms, and is an ideal human primary hepatic carcinoma cell line applied to fundamental research and preclinical application.

A Chinese medicine for helping the treatment of cancers, such as primary liver cancer, lung cancer and esophagus cancer, is prepared from 13 Chinese-medicinal materials including barbat skullcap, patrinia herb, zedoary, astragalus root, etc. Its advantage is high curative effect.

The invention discloses a culture medium and a culture method for constructing a liver tumor scaffoldless organoid. The culture medium comprises the following components: Advanced DMEM/F12, FBS, diabody, N-2, Noggin, B-27, EGF, FGF-10, Y-27632, A83-01, SB202190, R-Spondin, N-acetylcysteine, Nicotinamide, Wnt3A, HGF and PrimocinTM. The culture method comprises the steps of adding primary tumor cells separated and obtained into the above-mentioned special culture medium for resuspension, inoculating into an ultra-low adsorption U-shaped well plate after counting, and centrifugally culturing until organoids are formed. The culture medium and the culture method can realize in-vitro proliferation of primary liver cancer cells, can quickly construct the liver tumor scaffoldless organoids, and can maintain long-term stable growth of the liver tumor organoids. The tumor organoids formed by the culture medium and the culture method retain heterogeneity of tumor tissues of patients, and are suitable for drug sensitivity detection, tumor generation and development related research of in-vitro liver cancer chemotherapeutic drugs.

The invention relates to a medicament for treating liver cancer, which is prepared from 19 Chinese medicinal herbs including glossy ganoderma, antrodia cinnamomea, elecampane inula root, emblic leafflower fruit, meconopsis, giant cardiocrinum, rose mallow root, tabasheer, herpetospermum caudigerum wall, phymatopsis hastate, blumea leaf or twig, fructus phyllanthi, long pepper, dracocephalum tanguticum, liquoric root, cassia bark, areca seed, Chinese wolfberry fruit and litchee bark. The medicament is a pure natural Chinese medicine, does not have toxic or side effect and have injury to human bodies, has the effects of tonifying spleen and regulating flow of vital energy, cooling and refreshing and detoxicating and expelling toxic heat and polluted toxic qi of internal organs, and is mainly used for treating primary liver cancer. By long-term administration, the pathological changes of cells can be inhibited and prevented, appetite is improved obviously, and the immunity is enhanced.

The invention provides a prediction kit for the recurrence and metastasis after resection of an early primary carcinoma patient based on immune molecules. The prediction kit is characterized in that the prediction kit comprises interleukin 2 amplification detection reagent, reference gene amplification detection reagent, a reference substance, a positive reference substance and non-RNA enzyme water. The interleukin 2 gene messenger ribonucleic acid expression amount of the invention is taken as a marker which is obviously superior to clinical indexes that are currently used for predicting the postoperative recurrence and survival of the patients with liver cancer and as a prognosis judgment biomarker of the early patients with liver cancer.

A Chinese medicine í«Compound telini fly capsuleí» for treating primary liver cancer, lung cancer, rectum cancer, lymph cancer, and gynecologic cancer is prepared from 10 Chinese-medicinal materials including ginseng, telini fly, astragalus root, etc. Its preparing process is also disclosed.

Provided are compositions and methods to treat liver cancer and related disorders in human or veterinary individuals. Primary liver cancers, including those metastatic to other parts of the body, as well as cancers metastatic to the liver cancer, can be treated and/or prevented with the compositions and methods of the present invention. The methods comprise the administration of pharmaceutically acceptable gallium compositions, including gallium maltolate. Routes of administration include, without limitation, oral, intravenous, intratumoral, and into blood vessels as part of chemoembolization therapy. Some of the compositions and methods disclosed herein are applicable to cancers other than liver cancer.